Although minimal residual disease (MRD) has emerged as a valuable prognostic marker across several hematological malignancies, its use in chronic lymphocytic leukemia (CLL) is mostly limited to ...

Five hundred forty-two specimens of 150 children enrolled in the AML-Berlin-Frankfurt-Muenster (BFM) 98 study were analyzed by four-color immunophenotyping at up to four predefined time points during ...

Why minimal residual disease testing is the "gold standard" for some patients and providers. When Michael Ray went to his doctor for an annual checkup two years ago, he felt fine. But the bloodwork ...

The press release below was prepared by the American Association for Cancer Research. View the original here. Next-generation sequencing for minimal residual disease was highly sensitive and more ...

The upcoming webinar will delve into the advanced applications of Next Generation Flow™ in the analysis of Minimal Residual Disease (MRD) in Multiple Myeloma (MM). Dr. Juan Flores-Montero, a ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. Long-term monitoring for me means months to ...

Purpose Monitoring of residual disease (RD) by flow cytometry in childhood acute myeloid leukemia (AML) may predict outcome. However, the optimal time points for investigation, the best antibody ...